Posted 4 months ago
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)
ClinicalTrials.gov ID NCT05774951
Protocol number D8531C00002
Sponsor Astra Zeneca
Posted 4 months ago